Critical Survey: Alkermes (NASDAQ:ALKS) vs. CureVac (NASDAQ:CVAC)

CureVac (NASDAQ:CVAC – Get Free Report) and Alkermes (NASDAQ:ALKS – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends and valuation.

Insider & Institutional Ownership

17.3% of CureVac shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 2.1% of CureVac shares are owned by company insiders. Comparatively, 4.6% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares CureVac and Alkermes”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CureVac $70.74 million 14.78 $175.50 million $0.72 6.47
Alkermes $1.48 billion 5.12 $241.66 million ($0.02) -2,247.00

Alkermes has higher revenue and earnings than CureVac. Alkermes is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares CureVac and Alkermes’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CureVac 199.92% -23.03% -19.09%
Alkermes -0.02% 0.40% 0.19%

Analyst Recommendations

This is a breakdown of recent ratings for CureVac and Alkermes, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CureVac 1 0 0 0 1.00
Alkermes 1 5 10 1 2.65

Alkermes has a consensus target price of $55.73, indicating a potential upside of 24.02%. Given Alkermes’ stronger consensus rating and higher possible upside, analysts clearly believe Alkermes is more favorable than CureVac.

Volatility and Risk

CureVac has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500.

Summary

Alkermes beats CureVac on 10 of the 15 factors compared between the two stocks.

About CureVac

(Get Free Report)

CureVac is a biotechnology company founded in 2000 and headquartered in Tübingen, Germany. It focuses on messenger RNA (mRNA) technology, which uses genetic instructions to prompt cells to produce proteins that may help prevent or treat disease. The company has developed mRNA-based vaccine and therapeutic candidates for infectious diseases and cancer. Its programs have included COVID-19 vaccines and oncology research, and it has worked with pharmaceutical partners, including GSK, on mRNA vaccine development.

About Alkermes

(Get Free Report)

Alkermes plc is a biopharmaceutical company focused on developing and commercializing medicines for neuroscience-related conditions, including serious mental illness and addiction. Founded in 1987, the company has operations in the United States and Ireland, with its corporate headquarters in Dublin and major U.S. operations in Massachusetts. Its marketed medicines include Vivitrol, an extended-release injectable formulation of naltrexone used to treat alcohol dependence and to prevent relapse to opioid dependence after detoxification; Aristada, an injectable treatment for schizophrenia in adults; and Lybalvi, a medicine for schizophrenia and bipolar I disorder in adults.

Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.